Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Epigenetics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SETD2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SETD2 Active Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9/E. coli expressed. |
View SETD2 Products |
| Gene Delivery | SETD2 Promise-ORF / Lentivirus Full-length wild-type and loss-of-function mutant constructs for stable cell line generation. |
View SETD2 Products |
| Benchmark Ab | Anti-SETD2 Recombinant Antibody Sequence-derived recombinant positive control for Western Blot and IP. |
View SETD2 Products |
| Validator | SETD2 siRNA Set For knockdown verification and synthetic lethality validation. |
View SETD2 Products |
| Related Target A | NSD2 Homologous H3K36 methyltransferase; critical for selectivity counter-screening in multiple myeloma models. |
View NSD2 Products |
| Related Target B | WEE1 Synthetic lethal partner kinase; synergistic target for SETD2-deficient solid tumors. |
View WEE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic activity validation of SETD2 | Active catalytic domain (SET domain) recombinant proteins with verified purity (>95%) and theoretical MW. |
| Selectivity counter-screening against other H3K36 methyltransferases | Complete homolog panel (NSD1/2/3, ASH1L) strictly verified by mass spectrometry. |
| Lack of controls | Recombinant benchmark antibodies derived from clinical/literature sequences. |
| False positives in cellular phenotype assays | Sequence-verified siRNA sets and Lentivirus-ORF constructs for target-specific validation. |
Live SETD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SETD2 therapeutics is intensifying, with major players shifting focus from traditional enzymatic inhibitors to synthetic lethal strategies and targeted protein degradation (PROTACs). As first-generation SETD2 inhibitors (such as EZM0414) progress through clinical trials for hematological malignancies, the next wave of R&D is targeting SETD2-deficient solid tumors (e.g., clear cell renal cell carcinoma) through combination therapies targeting DNA damage repair pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Epizyme (Ipsen), Ryvu Therapeutics | Multiple Myeloma, DLBCL | High-throughput methyltransferase activity assay (Need highly active SETD2 recombinant protein) |
| Synthetic Lethal Therapeutics | AstraZeneca, Schrodinger | SETD2-deficient ccRCC | Isogenic cell line validation (Need SETD2 siRNA/Lentivirus knockout systems) |
| PROTACs / Degraders | Academic consortia, Biotech startups | Solid Tumors, Hematological | Target engagement and degradation assays (Need high-purity SETD2 protein & benchmark antibodies) |